Skip to main content

Table 1 Pharmacokinetic parameters of the CK-1δ inhibitor IGS2-7 in plasma and brain following a single intraperitoneal (Dose: 2 mg.kg−1) and oral (Dose: 10 mg.kg−1) administration in male BALB/c mice

From: Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia

Route Matrix Tmax (h) Cmax (ng.ml−1) AUClast (h.ng.mL−1) AUCinf (h.ng.mL−1) MRTlast (h) MRTinf (h)
i.p Plasma 0.5 224.51 1577 1689.27 6.07 7.87
  Braina 1.0 670.56 3202.45 NR 3.40 8.64
p.o Plasma 0.5 1120.42 6692.81 6750.19 4.61 4.82
  Braina 2.0 3940.51 23976.84 24232.22 4.73 4.99
  1. NR not reported since AUCinf is 20 % greater than AUClast, MRT mean residence time
  2. aBrain concentration and AUC expressed as ng.g−1 and h.ng.g−1 respectively